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688Objective: With the increasing longevity of heart transplant recipients, the long-term effects of cyclosporine on
renal function have become more evident. Highly sensitive, early, and effective monitoring of posttransplant renal
function is still being researched. This study aimed to evaluate the prognostic value of cystatin C for patients after
heart transplantation.
Methods: Seventy-three long-term recipients of a heart transplant more than 5 years before the study start were
included in the analysis with a follow-up of 4 years. Serum creatinine, renal glomerular filtration rate calculated by
the Modification of Diet in Renal Disease formula, and serum cystatin C levels were collected, and risk factors for
renal dysfunction were assessed. Statistical analysis was performed for all patients.
Results: Univariate analysis showed a prognostic impact of antihypertensive medication and onset of diabetes
(P< .001) on renal failure after transplantation. Multivariate analysis yielded cystatin C measured at the study
start as a superior prognostic parameter for all time points (area under the receiver operating characteristic 12
months: 0.963; 24 months: 0.910; 48 months: 0.949) compared with the conventionally used creatinine levels.
Conclusions: Our results showed an enormous potential of serum cystatin C as an early prognostic and easy to
obtain biomarker for renal dysfunction after heart transplantation. (J Thorac Cardiovasc Surg 2010;140:688-93)Renal dysfunction is one of the most common and threaten-
ing complications in patients after heart transplantation
(HTx). Renal failure after the transplantation of a nonrenal
organ complicates medical management and leads to in-
creased morbidity and mortality.1,2 The risk of chronic
failure and the need for long-term renal replacement therapy
have increased and will increase further because of amelio-
rated longevity in the overall population of transplant recip-
ients. A direct proportion of an increasing rate of chronic
renal failure with the longevity of HTx recipients has already
been shown.3
As reported previously, approximately 7% of patients be-
come dialysis dependent within 5 to 10 years after HTx. Fur-
thermore, the occurrence of chronic renal failure among
patients with a nonrenal transplant has been associated
with a more than 4 times higher mortality.4 Kidney disease
in nonrenal transplant recipients may also trigger the occur-
rence of concomitant diseases, such as osteoporosis, anemia,
and hypertension.
A crucial point for studies on renal function after HTx
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The Journal of Thoracic and Cardiovascular Surgcreatinine (sCr) is widely used as marker for renal function,
but it depends on various nonrenal factors such as muscle
mass, physical activity, and protein intake.5 Furthermore,
major changes occur late in the course of progressive renal
impairment. Usual markers of kidney function, such as sCr,
creatinine clearance, and calculated creatinine clearance us-
ing the Cockcroft–Gault equation, have been shown to be
inaccurate in predicting a glomerular filtration rate (GFR)
less than 80 mL/min/1.73 m2.6 The use of cystatin C as
a marker of GFR was first proposed in 1985.7 Cystatin C
is produced by nucleated cells at a constant rate.8 It is
cleared from the blood by glomerular filtration and is
then reabsorbed and catabolized in proximal tubular cells
without reentering the circulation.9 Therefore, cystatin C
has been suggested to be an excellent marker of GFR,10 un-
related to weight and gender and unaltered by inflammatory
conditions.11
The present study evaluated the prognostic impact of cys-
tatin C in a population of recipients 5 to 10 years after HTx.
To find an easy to obtain parameter for the prediction of late
renal failure means to minimize patients’ risk for dialysis-
dependent renal failure and to optimize patients’ graft sur-
vival through the reduction of the risk for the onset of
immunosuppressive-associated renal hypertension after
transplantation.MATERIALS AND METHODS
Patients
Seventy-three patients (19 female and 54 male, with a median age of 59.5
years [23–74 years]) at 5 to 10 years after HTx were included in the prospec-
tive observational study. The median time posttransplantation at inclusionery c September 2010
Abbreviations and Acronyms
AUROC ¼ area under the receiver operating
characteristic
CNI ¼ calcineurin inhibitor
EMB ¼ endomyocardial biopsy
GFR ¼ glomerular filtration rate
HTx ¼ heart transplantation
MDRD ¼ Modification of Diet in Renal Disease
MMF ¼ mycophenolate mofetil
ROC ¼ receiver operating characteristics
sCr ¼ serum creatinine
Kniepeiss et al Cardiothoracic Transplantationwas 89 months (61–119 months), and the median follow-up was 48 months.
Indications for HTx were dilative (78.1%) and ischemic (21.9%) cardiomy-
opathy. Patients with renal dysfunction requiring kidney transplantation
were excluded from the analysis.Immunosuppression
During the first week after HTx, all patients received induction therapy
with antilymphocyte globulin (Lymphoglobulin, Pasteur Merieux, Leimen,
Germany). Calcineurin inhibitors (CNIs) and mycophenolate mofetil
(MMF) were initiated on days 2 to 4, and standard trough levels were in-
tended to be reached on day 7. Aprednisolone was given at 15 mg/d and ta-
pered after 6 months.
For maintenance therapy, all patients received triple drug immunosup-
pression consisting of a CNI, MMF, and aprednisolone. Cyclosporine
trough levels were intended to be between 100 and 150 ng/mL, tacrolimus
trough levels were between 3 and 8 ng/mL, and MMF levels were approx-
imately 1 mg/mL. Twenty patients were administered everolimus in combi-
nation with cyclosporine and aprednisolone. The indications for switching
to everolimus have been described.12 Everolimus was administered in
patients with blood levels between 3 and 8 ng/mL. Cyclosporine levels in
combination with everolimus were between 70 and 90 ng/mL.Rejection Monitoring
Endomyocardial biopsies (EMBs) were performed weekly during the
first month and monthly during the first 6 months after HTx. In stable
HTx recipients, EMBs were performed once per year. In cases of clinical
deterioration, EMB was part of our diagnostics. The results of EMBs
were classified according to the International Society of Heart and Lung
Transplantation guidelines. Rejections greater than grade 2 were treated
with steroids or polyclonal antibodies.
T
XMonitoring of Kidney Function
Patients were monitored after HTx on an outpatient basis, and among
other routine laboratory parameters, sCr, cystatin C, and GFR, calculated
by the Modification of Diet in Renal Disease (MDRD) formula,13 were
determined.
SCr levels were determined using the Jaffe-Method, and MDRD equation
was calculated following the formula 1863 (sCr [mg/dL]1.154)3 age0.203
in male patients and 1863 (sCr [mg/dL]1.154)3 age0.2033 0.742 in female
patients every 3 months. For cystatin C measurement, an automated homo-
geneous immunoassay using latex or polystyrene particles coated with
cystatin C-specific antibodies based on nephelometry (particle-enhanced
nephelometric immunoassay; Dade Behring, Marburg, Germany) was
used exactly as described by the manufacturer.14The Journal of Thoracic and CaEvaluation of Risk Factors for Kidney Dysfunction
Risk factors for renal dysfunction were evaluated. As preoperative risk
factors, the appearance of preexisting renal failure, hypertension, and diabe-
tes mellitus were analyzed. The peri- and postoperative factors were use of
renal replacement therapy, episodes of treated rejection, septic episodes, and
use of nephrotoxic antimicrobials. Long-term factors were the presence or
development of hypertension, diabetes mellitus or hyperlipidemia, clinical
episodes of urinary tract infection, immunosuppressive therapy with dosage
and trough levels, and duration of survival after transplantation.
Definition of Renal Impairment
Renal impairment was defined using the GFR calculated by the MDRD
according to the Kidney Disease Outcomes Quality Initiative guidelines.15
A cutoff level less than and more than 30 mL/min/1.73 m2 was used.16,17
Statistical Analysis
All data are presented as median and interquartile range, unless otherwise
noted. Data were tested for normality by the Kolmogorov–Smirnov test and
the Shapiro–Wilks test. For comparison of 2 groups, continuous variables
were analyzed by Student t test or U test. Binary logistic regression models
were used to assess the influence of GFR calculated by the MDRD formula
and serum cystatin C on renal function at 24 and 48 months after HTx. Re-
ceiver operating characteristic (ROC) curve analysis was used to express the
diagnostic accuracy of cystatin C and sCr for renal function. The Youden
index was used to determine the best cutoff for the evaluated parameters.
The ROC curves were compared using the difference between the area
test.16 An overall statistical analysis was performed. Data were evaluated us-
ing the Statistical Package for the Social Sciences version 15.0 (SPSS Inc,
Chicago, IL). Youden index and ROC curve comparison were done using
MedCalc version 10.0 (MedCalc Software, Mariakerke, Belgium).
RESULTS
In total, all 73 patients were analyzed. Indications for HTx
and all baseline characteristics at study entry are listed in
Table 1. Data were divided according to gender and are
given as median and interquartile range. All factors possibly
influencing the onset of renal failure are given. As can be
seen from Table 1, there were no statistically significant dif-
ferences. GFR calculated according to the MDRD formula
differed in both groups, but the difference was not statisti-
cally significant. For immunosuppression, 87.8% of patients
received cyclosporine. 61.1% of patients received everoli-
mus, 62.2% of patients received tacrolimus, and 11.1% of
patients received MMF. Throughout the study period,
dialysis-dependent renal failure developed in 7 patients.
The median sCr level at the study start was 0.9 (0.8–1.3)
mg/dL, the median GFR calculated by the MDRD formula
was 72.8 (54.9–84.3) mL/min/1.73 m2, and the median cys-
tatin C level at baseline was 1.4 (0.88–1.83) mg/dL.
Figure 1 shows the percentage of patients with normal re-
nal function according to all 3 measurements compared at
each time point. SCr and GFR calculated according to the
MDRD are simulating normal kidney function in 47%,
48%, and 36% of patients and 79%, 82%, and 74% of pa-
tients, respectively, at all time points, whereas serum cysta-
tin C is normal in only 11% of the patients at study start, 9%
of patients after 24 months of the observation period, and
6.5% of patients at study end.rdiovascular Surgery c Volume 140, Number 3 689
TABLE 1. Baseline characteristics according to gender
Male
(n ¼ 54)
Female
(n ¼ 19)
P
value
Age (median, range) 62 (49–68) 65 (60–69) NS
Indications for HTx (%)
Dilated cardiomyopathy 77.6 80 NS
Ischemic cardiomyopathy 22.4 20 NS
Months after transplantation 111 (51–118) 86 (84–111) NS
Antilipemics at study start (%) 81.6 92.3 NS
Antihypertensive medication
study start (%)
85.7 84.6 NS
Diabetes at study start (%) 32.71 38.6 NS
sCr study start (mg/dL) 1.7 (1.2–2.3) 1.2 (1.1–1.9) NS
GFR at study start
(mL/min/1.73 m2)
42.8 (32.3–67.5) 60 (37.4–61) NS
Cystatin C at study start
(mg/dL)
1.9 (1.4–2.7) 1.8 (1.4–2.6) NS
New onset of dialysis during
the study (%)
4 (9) 3 (16) NS
Data are presented as median and interquartile range. HTx, Heart transplantation;
sCr, serum creatinine; GFR, glomerular filtration rate; NS, not significant.
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T
XAll included patients survived the peri-interventional pe-
riod. Three patients died during the observation period (1 sui-
cide, 2 infections). Six patients had rejections during the
observation period. All rejections were managed with antith-
ymocyte globulin (Lymphoglobulin) and steroid therapy.
Regression analysis yielded that preexisting hypertension
and existing diabetes mellitus at the study start were the only
risk factors that showed a significant (P ¼ .008) impact on
the development of renal impairment after HTx during the
observation period. There was no significant impact of gen-
der on impaired kidney function.
Everolimus as a immunosuppressive agent did not signifi-
cantly influence renal function at the study end point. By0
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FIGURE 1. Comparison of the courses of the 3 prognostic systems. SCr
and GFR calculated by the MDRD formula are seen to simulate normal kid-
ney function for more than half of the patients at all time points. MDRD,
Modification of Diet in Renal Disease.
690 The Journal of Thoracic and Cardiovascular Surgtaking all other immunosuppressive agents into account, sta-
tistical analysis revealed no significant impact of immunosup-
pression on the incidence of chronic renal failure (P> .05).
sCr, GFR calculated by the MDRD formula, and cystatin
C were analyzed and compared with respect to sensitivity
and specificity. The statistical results are shown in
Table 2. At both time points, cystatin C showed clear prog-
nostic significance with a P value of less than .05, whereas
GFR calculated by the MDRD formula did not show signif-
icant prognostic validity. Serum cystatin C levels and sCr
levels were strongly correlated at the beginning (r ¼ .859,
P ¼ .0001) and end (r ¼ .886, P ¼ .0001) of the study
(Figure 2).
Multivariate Analysis for Predictive Value of
Cystatin C
Parameters that were considered as independent predic-
tors for renal impairment after HTx were used for a logistic
regression analysis. This revealed cystatin C measured at the
study start as the superior independent predictor (P¼ .0001)
for renal failure at 24 and 48 months after HTx for the whole
patient set.
Cystatin C measured at the study start showed a superior
diagnostic accuracy to detect renal impairment as defined by
the GFR calculated according to the MDRD equation 24 and
48 months thereafter (area under the receiver operating char-
acteristic [AUROC] 24 months ¼ 0.96; AUROC 48
months¼ 0.95) (Figure 3) in the whole patient set compared
with the sCr measured at the study start (AUROC 24
months ¼ 0.89; AUROC 24 months ¼ 0.89) (Table 3).
The difference was not significant at any time point. The cys-
tatin C level that gave the best specificity and sensitivity to
detect renal impairment calculated after the Youden index
for the presented patients was 0.9596. The comparison of
the AUROC did not reveal a statistically significant differ-
ence between the ROC curves.
DISCUSSION
In the present study, parameters for renal dysfunction and
damage of the kidney in patients after HTx were evaluated
and compared. SCr is widely used as a marker for renal func-
tion, but it depends on various nonrenal factors, and major
changes will occur late in the course of progressive renal im-
pairment. In HTx recipients, sCr is even less accurate be-
cause this population has a reduced muscular mass.
Moreover, chronic therapy with corticosteroids may impair
this situation.17 The clinical use of cystatin C has been stud-
ied, and a significant superior sensitivity of cystatin C in
comparison with creatinine was shown.8 Studies of cystatin
C in HTx recipients are rare, and because of rather small co-
horts, the results were not encouraging.18 In contrast, the re-
sults of our study confirmed cystatin C as an early prognostic
marker of patients with renal dysfunction after HTx for a rel-
atively large patient cohort.ery c September 2010
TABLE 2. Prognostic value of serum creatinine and serum cystatin C
Time point Parameter P value OR CI 95% CI 95%
Study start sCr .119 1.07 0.98 1.155
Cystatin C 0 60011090 2965.68 1.21434Eþ12
24 mo after study start sCr .469 0.98 0.92 1.04
Cystatin C 0 813.04 21.31 31014.23
48 mo after study start sCr .451 0.97 0.91 1.04
Cystatin C .005 1345.08 8.79 205818.46
At each time point, cystatin C demonstrated a prognostic significance (P<.05), whereas sCr had no influence on the development of renal failure. CI,Confidence interval; OR, odds
ratio; sCr, serum creatine.
Kniepeiss et al Cardiothoracic TransplantationSCr, GFR calculated by the MDRD formula, and cystatin
C were analyzed and compared with respect to sensitivity
and specificity. At all time points, cystatin C showed a clear
prognostic significance with a P value of less than .05,
whereas sCr and GFR calculated by the MDRD formula
did not show significant prognostic validity. Only 50% of
the evaluated patients (eg, only 50% of long-term HTx re-
cipients with high risks for renal impairment) were classified
correctly by conventional measurements regarding their kid-
ney function. Regarding cystatin C, only 11% of the patients
had normal kidney function at the start of the study, which
worsened during the course of the study (Figure 1).
Causes for renal dysfunction after transplantation are mul-
tifactorial, but CNI-associated renal impairment and renal
failure have been recognized since the early days of its
use. Renal dysfunction during treatment with CNI can be di-
vided into acute and chronic forms.19 Acute toxicity is often
associated with high blood levels of the drugs and is mainly
observed in the early postoperative time. This type is charac-
terized with a sudden increase in creatinine level and is inFIGURE 2. There is a strong correlation (r ¼ 0.886; P ¼ .0001) betwe
The Journal of Thoracic and Cageneral reversible after dose reduction. In cases of early
chronic CNI-induced nephrotoxicity, dose reduction is es-
sential and can ameliorate chronic nephropathy. Therefore,
the early detection of renal complications and the possibility
of identifying patients with a higher risk for renal complica-
tions are important steps to avoid progressive renal failure.
Cystatin C may be able to detect renal deterioration very
early, so that reversibility is still an option.
Chronic CNI nephrotoxicity occurs in the later course
after transplantation and is often irreversible after dose
reduction because of advanced morphologic changes of
the kidneys.20 Myers and colleagues21 evaluated the CNI-
related renal structural and functional changes of kidneys
in patients after transplantation. A progressive decrease in
GFR, a concomitant decrease in renal plasma flow, and an
increase in renal vascular resistance associated with sys-
temic hypertension were described in the beginning. Renal
biopsies presented glomerulosclerosis, striped interstitial fi-
brosis, and afferent arteriolopathy. In cases of irreversible
CNI nephrotoxicity, the evaluation and therapy of otheren sCr and serum cystatin C after the 48-month observation period.
rdiovascular Surgery c Volume 140, Number 3 691
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FIGURE 3. Serum cystatin C shows a high sensitivity and specificity
(AUROC¼ 0.96) with a confidence interval of 0.915 to 1.010 and a signif-
icance of P ¼ .0001 for the long-term prognosis of renal failure after HTx.
AUROC, Area under the receiver operating characteristic; CI, confidence
interval.
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T
Xrisk factors are crucial to avoid progressive renal impair-
ment. Also, the detection of renal deterioration at an early
stage is essential and cystatin C could contribute.
In regard to the dose of CNI, the correlation to renal func-
tion is still controversial. Consensus that the drug is respon-
sible for renal failure exists, and irreversible renal damage
has been reported even with low doses of cyclosporine.22
Several studies have suggested that CNI nephrotoxicity
could result from individually determined susceptibility.3,23
Although most studies did not show a correlation between
CNI levels and renal impairment in patients after HTx, it
is generally agreed that efficient monitoring of
cyclosporine blood levels and renal function is substantial
in maintaining renal function.
Because of the high risk of organ rejection and loss of
graft with changes in immunosuppression, conversion strat-
egies are usually performed at a late time point when renalTABLE 3. Diagnostic accuracies assessed by receiver operating
characteristic analysis of cystatin C and serum creatinine measured
at study start regarding renal function 24 and 48 months after study
start
AUROC (CI, 95%) Range
sCr at study start to RI 24 mo .87 0.610–1.096
Cystatin C at study start to RI 24 mo .93 0.865–0.990
sCr at study start to RI 48 mo .88 0.781–0.974
Cystatin C at study start to RI 48 mo .96 0.916–1.005
AUROC, Area under the receiver operating characteristic; CI, confidence interval;
sCr, serum creatine; RI, renal insufficiency.
692 The Journal of Thoracic and Cardiovascular Surgfailure is irreversible. New immunosuppressive agents
such as everolimus offered the possibility to change the
management of CCI therapy. Zuckermann and Aliabadi24
evaluated CNI minimization protocols in HTx recipients
and approved the protocols as possible and safe. Prospective
randomized studies are necessary to confirm these results
and to assess their influence on chronic renal failure. Our
study showed that an immunosuppressive regimen with
everolimus had no influence on renal impairment. We sup-
pose that the lowest CNI target levels were not reached in
this cohort and that further benefit of CNI withdrawal may
be possible. Even if a direct correlation between renal im-
pairment and CNI-free immunosuppressive therapy was
not confirmed in this study, we observed that every patient
whose immunosuppressive therapy was switched because
of elevated cystatin C levels stabilized in terms of renal func-
tion throughout the whole time period studied. Ojo25
showed that 1.5% to 2% of HTx recipients per year newly
develop chronic renal failure requiring hemodialysis. This
was not true for our patient cohort, possibly because of the
early switch in immunosuppression as a result of cystatin
C-based monitoring of kidney function.
In addition to CNI-associated nephropathy, there are many
causes of renal impairment. Hamour and colleagues26 em-
phasize that chronic kidney disease after HTx is not influ-
enced by a CNI regimen but by several other risk factors.
Renal disease before transplantation, perioperative hemody-
namic insults to the kidneys, nephrotoxic effects of other
drugs, dyslipidemia, hypertension, and diabetes mellitus
can all contribute to chronic renal failure in recipients of non-
renal organs.26 The results of our study revealed pretrans-
plant hypertension and diabetes mellitus as risk factors for
the development of chronic renal failure after transplantation.
Adequate therapy needs to be administered subsequently.
Plasma cystatin C levels have recently been suggested as
markers for cardiovascular mortality or renal failure subse-
quent to cardiovascular morbidity or heart surgery.27,28
Cystatin C has even been proposed as an early biomarker
for the prediction of possible renal failure in patients
undergoing bypass grafting.29 This clearly confirms our re-
sults of cystatin C as an early prognostic marker for renal
failure after HTx.
CONCLUSIONS
Preventive measures to avoid progressive decline in renal
function should be taken at an early stage. We suggest that
cystatin C be investigated regularly in patients after HTx
to recognize renal dysfunction in time and to prevent chronic
renal failure. After the detection of a potential risk for pa-
tients to develop chronic kidney disease after HTx, a switch
of immunosuppression and further measurements (eg, inulin
plasma clearance) should be performed. Nevertheless, fur-
ther randomized prospective trials are needed to confirm
the role of cystatin C in patients after HTx.ery c September 2010
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